(Q36075911)

12 August 2017

1 reference

title

Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? (English)

1 reference

12 August 2017

7

Kevin Marsh

1 reference

12 August 2017

1

Alexis Nzila

1 reference

12 August 2017

Edwin Ochong

2

1 reference

12 August 2017

Eunice Nduati

3

1 reference

12 August 2017

Kokwaro Gilbert

4

1 reference

12 August 2017

Peter Winstanley

5

1 reference

12 August 2017

Steve Ward

6

1 reference

12 August 2017

publication date

1 May 2005

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

12 August 2017

published in

1 reference

12 August 2017

volume

99

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

341-346

1 reference

Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Persistence of antibiotic resistant bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

The biological cost of antibiotic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

The puzzling links between malaria transmission and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

The cost of antibiotic resistance from a bacterial perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Malaria control and the evolution of drug resistance: an intriguing link.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

The development of Lapdap, an affordable new treatment for malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five from south-western Uganda with uncomplicated falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Artemether-lumefantrine for uncomplicated malaria: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Antifolate antimalarial resistance in southeast Africa: a population-based analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Yeast as a model system to study drugs effective against apicomplexan proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

The dynamics of drug resistance in Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2004.07.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRSTMH.2004.07.002

1 reference

12 August 2017

1 reference